Initiate the Phase 2 clinical study
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- Q4 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“initiating the Phase 2 clinical study in the third quarter of 2021”
What we found
Evidence strength A What the grades mean
The company committed to initiating the Phase 2 study in Q3 2021, but later filings clarify that patient enrollment for the study began in the fourth quarter of 2021.
-
A Harrow Health, Inc. 10-Q filed 2022-05-05
“Melt began enrolling patients in its Phase 2 study for MELT-300 during the fourth quarter of 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 clinical study
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Harrow Health, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-HROW-023386 · Corrections policy